TESSERACT 2

Purpose of this Study

This study lasts for 90 days. People who join will wear a cloth cap with special sensors on their head. A computer will help decide which group they are in. Some people will get a real treatment, and others will be in a control group, which means they do not get the real treatment. After each of the one, two, or three treatment sessions, people will answer ten questions about how they feel. A doctor or helper will also check how their brain and body are working for five minutes. One day after the treatment, they will get a brain scan and a test to see how blood moves in their brain. They will also have short check-ups in person on day one and day four, a phone call on day thirty, and another in-person visit on day ninety.

Who Can Participate?

Eligibility

This study is for people who had a stroke less than one day ago. They must have serious problems with how their brain works. A scan must show that a big blood vessel in their brain is blocked. Another scan must show that part of their brain can still be saved. They also cannot be treated with special tools that remove blood clots.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

The goal of this study is to find the best amount of a gentle electrical signal that can be safely used to help people who have had a stroke. The signal is sent to the brain using a method called tDCS. It works by calming brain cells that are not getting enough oxygen and nutrients because of a blocked blood vessel. This may help those cells need less energy, get more blood, and survive better during the stroke.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

Transcranial electrical Stimulation in Stroke EaRly After onset
Clinical Trial 2

Principal Investigator

Wuwei
Feng

Protocol Number

PRO00116469

NCT ID

NCT06440707

Phase

II

Enrollment Status

Open to Enrollment